| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1986PNAS...83.7462O |
| P356 | DOI | 10.1073/PNAS.83.19.7462 |
| P932 | PMC publication ID | 386738 |
| P698 | PubMed publication ID | 3532115 |
| P5875 | ResearchGate publication ID | 19630036 |
| P50 | author | Robert M. Chanock | Q776523 |
| Bernard Moss | Q822617 | ||
| Brian R. Murphy | Q65658906 | ||
| P2093 | author name string | Collins PL | |
| Johnson PR | |||
| Olmsted RA | |||
| Prince GA | |||
| Elango N | |||
| P2860 | cites work | Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine | Q34206177 |
| Respiratory syncytial virus envelope glycoprotein (G) has a novel structure | Q35563719 | ||
| Expression of the major glycoprotein G of human respiratory syncytial virus from recombinant vaccinia virus vectors | Q35585367 | ||
| Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein | Q35596022 | ||
| Respiratory syncytial virus fusion glycoprotein: nucleotide sequence of mRNA, identification of cleavage activation site and amino acid sequence of N-terminus of F1 subunit | Q36137180 | ||
| Immunochemical identification of viral and nonviral proteins of the respiratory syncytial virus virion. | Q36329541 | ||
| Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. | Q36330347 | ||
| Functional expression in primate cells of cloned DNA coding for the hemagglutinin surface glycoprotein of influenza virus | Q36367356 | ||
| Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein | Q36486699 | ||
| cDNA cloning and transcriptional mapping of nine polyadenylylated RNAs encoded by the genome of human respiratory syncytial virus | Q36591444 | ||
| Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus | Q36858777 | ||
| Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats | Q36903965 | ||
| Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques | Q36952733 | ||
| Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus | Q37579808 | ||
| Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies | Q40181974 | ||
| An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine | Q40940832 | ||
| Respiratory syncytial virus polypeptides. III. The envelope-associated proteins | Q45794076 | ||
| Cell surface expression of the influenza virus hemagglutinin requires the hydrophobic carboxy-terminal sequences | Q45794193 | ||
| Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus | Q45794683 | ||
| Sindbis virus mutants selected for rapid growth in cell culture display attenuated virulence in animals | Q45804351 | ||
| Monoclonal antibodies protect against respiratory syncytial virus infection in mice | Q45804443 | ||
| Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. | Q45819313 | ||
| Purification and characterization of the respiratory syncytial virus fusion protein | Q45828986 | ||
| Fusion glycoprotein of human parainfluenza virus type 3: nucleotide sequence of the gene, direct identification of the cleavage-activation site, and comparison with other paramyxoviruses | Q45836669 | ||
| Two distinct subtypes of human respiratory syncytial virus | Q45848624 | ||
| Live respiratory syncytial virus vaccine administered parenterally | Q45889949 | ||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| Vaccinia virus | Q1986297 | ||
| P304 | page(s) | 7462-7466 | |
| P577 | publication date | 1986-10-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity | |
| P478 | volume | 83 |
| Q35210844 | A General Overview of Viral Vaccine Development |
| Q34492100 | A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism |
| Q41210925 | A point mutation in the F1 subunit of human respiratory syncytial virus fusion glycoprotein blocks its cell surface transport at an early stage of the exocytic pathway |
| Q34948645 | A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles |
| Q42068164 | A prototype recombinant vaccine against respiratory syncytial virus and parainfluenza virus type 3. |
| Q33578748 | A recombinant influenza virus vaccine expressing the F protein of respiratory syncytial virus |
| Q41137179 | A recombinant varicella vaccine harboring a respiratory syncytial virus gene induces humoral immunity. |
| Q37252613 | A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice |
| Q33787073 | A single amino acid change in the Newcastle disease virus fusion protein alters the requirement for HN protein in fusion |
| Q34142727 | A wild goose metapneumovirus containing a large attachment glycoprotein is avirulent but immunoprotective in domestic turkeys |
| Q34616642 | Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins |
| Q35893983 | An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice |
| Q33178217 | An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein |
| Q41853385 | Antigenic and genetic variability of human metapneumoviruses |
| Q36919232 | Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity |
| Q33795720 | Antigenic relationships among human rotaviruses as determined by outer capsid protein VP4 |
| Q39579940 | Antigenic structure of human respiratory syncytial virus fusion glycoprotein. |
| Q28360752 | Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro |
| Q39553080 | Baculovirus expression of the fusion protein gene of bovine respiratory syncytial virus and utility of the recombinant protein in a diagnostic enzyme immunoassay |
| Q40880160 | Baculovirus vectors expressing F proteins in combination with virus-induced signaling adaptor (VISA) molecules confer protection against respiratory syncytial virus infection |
| Q36643763 | Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection |
| Q33801890 | CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment |
| Q43690717 | CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein |
| Q36194078 | Carriers for the delivery of a vaccine against respiratory syncytial virus |
| Q51696281 | Characteristics of immunity induced by viral antigen or conferred by antibody via different administration routes. |
| Q37002523 | Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV |
| Q33793103 | Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine |
| Q45842838 | Comparison of caprine, human and bovine strains of respiratory syncytial virus |
| Q36888993 | Comparison of the relative roles of the F and HN surface glycoproteins of the paramyxovirus simian virus 5 in inducing protective immunity |
| Q36680205 | Complementation between avirulent Newcastle disease virus and a fusion protein gene expressed from a retrovirus vector: requirements for membrane fusion |
| Q36823304 | Conformational studies of a short linear peptide corresponding to a major conserved neutralizing epitope of human respiratory syncytial virus fusion glycoprotein |
| Q45864182 | Construction of a pigeonpox virus recombinant: expression of the Newcastle disease virus (NDV) fusion glycoprotein and protection of chickens against NDV challenge |
| Q36784384 | Contribution of measles virus fusion protein in protective immunity: anti-F monoclonal antibodies neutralize virus infectivity and protect mice against challenge |
| Q45860348 | Correlation between the reactivity patterns of monoclonal antibodies to distinct antigenic sites on HN glycoprotein and their protective abilities in Sendai (6/94) virus infection |
| Q36782773 | Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins. |
| Q26782411 | Development of next-generation respiratory virus vaccines through targeted modifications to viral immunomodulatory genes |
| Q36679855 | Effectiveness of enteric immunization in the development of secretory immunoglobulin A response and the outcome of infection with respiratory syncytial virus |
| Q30933288 | Efficient generation of respiratory syncytial virus (RSV)-neutralizing human MoAbs via human peripheral blood lymphocyte (hu-PBL)-SCID mice and scFv phage display libraries |
| Q42180923 | Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation |
| Q89860924 | Engineering of Live Chimeric Vaccines against Human Metapneumovirus |
| Q41557807 | Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350. |
| Q45722195 | Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates |
| Q40041314 | Evolutionary pattern of human respiratory syncytial virus (subgroup A): cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein |
| Q39289377 | Exogenous, TAP-independent lysosomal presentation of a respiratory syncytial virus CTL epitope |
| Q36919535 | Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity |
| Q37153108 | Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. |
| Q41235315 | Frame shift mutations as a novel mechanism for the generation of neutralization resistant mutants of human respiratory syncytial virus. |
| Q40060807 | Fusion mutants of Newcastle disease virus selected with monoclonal antibodies to the hemagglutinin-neuraminidase |
| Q33603913 | HLA class I-restricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion protein |
| Q39486066 | High genetic diversity of the attachment (G) protein of human metapneumovirus. |
| Q35488618 | Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection |
| Q26822938 | Human Metapneumovirus: lessons learned over the first decade |
| Q36827256 | Human liver plasma membranes contain receptors for the hepatitis B virus pre-S1 region and, via polymerized human serum albumin, for the pre-S2 region |
| Q45787436 | Human parainfluenza virus type 3: Analysis of the cytoplasmic tail and transmembrane anchor of the hemagglutinin-neuraminidase protein in promoting cell fusion |
| Q43866620 | Human respiratory syncytial virus surface glycoproteins F, G and SH form an oligomeric complex |
| Q45728526 | Identification of a novel human leucocyte antigen-A*01-restricted cytotoxic T-lymphocyte epitope in the respiratory syncytial virus fusion protein |
| Q33815412 | Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein |
| Q33785124 | Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles. |
| Q36920250 | Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. |
| Q34014799 | Immune-mediated disease pathogenesis in respiratory syncytial virus infection |
| Q37940915 | Immunity to human and bovine respiratory syncytial virus |
| Q36650105 | Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells |
| Q36866184 | Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection |
| Q40067229 | Immunodominant T-cell epitope on the F protein of respiratory syncytial virus recognized by human lymphocytes |
| Q40772847 | Immunofluorescence assay for detection of human metapneumovirus-specific antibodies by use of baculovirus-expressed fusion protein. |
| Q39822523 | Immunogenic properties of RSV-B1 fusion (F) protein gene-encoding recombinant adenoviruses |
| Q45757011 | Immunological response of mice to the bovine respiratory syncytial virus fusion glycoprotein expressed in recombinant baculovirus infected insect cells |
| Q39007664 | Immunopathogenesis associated with formaldehyde-inactivated RSV vaccine in preclinical and clinical studies |
| Q45737617 | Immunoregulatory role of secreted glycoprotein G from respiratory syncytial virus |
| Q51812238 | Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity. |
| Q35856437 | Inducible translational regulation of the NF-IL6 transcription factor by respiratory syncytial virus infection in pulmonary epithelial cells. |
| Q40101115 | Induction of a neutralizing immune response to human respiratory syncytial virus with anti-idiotypic antibodies |
| Q33984333 | Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates |
| Q37069783 | Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses. |
| Q40812866 | Influence of antigen conformation and mode of presentation on the antibody and protective responses against human respiratory syncytial virus: relevance for vaccine development |
| Q39289416 | Influence of respiratory syncytial virus strain differences on pathogenesis and immunity |
| Q36873331 | Mapping an antibody-binding site and a T-cell-stimulating site on the 1A protein of respiratory syncytial virus |
| Q34651319 | Modification of the trypsin-dependent cleavage activation site of the human metapneumovirus fusion protein to be trypsin independent does not increase replication or spread in rodents or nonhuman primates |
| Q54222067 | Molecular Characterization of Respiratory Syncytial Virus in Children with Repeated Infections with Subgroup B in the Philippines. |
| Q33842098 | Molecular epidemiology and evolution of human respiratory syncytial virus and human metapneumovirus |
| Q39602758 | N-glycans of F protein differentially affect fusion activity of human respiratory syncytial virus |
| Q34990420 | Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease |
| Q27486621 | Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function |
| Q40130924 | Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. |
| Q34249859 | New insights for development of a safe and protective RSV vaccine |
| Q45391629 | Newcastle disease virus F glycoprotein expressed from a recombinant vaccinia virus vector protects chickens against live-virus challenge |
| Q40053603 | Nucleic acid-based vaccines targeting respiratory syncytial virus: delivering the goods |
| Q34313909 | Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses |
| Q45740945 | Oral immunization of mice with transgenic tomato fruit expressing respiratory syncytial virus-F protein induces a systemic immune response |
| Q90211672 | Parainfluenza virus 5 (PIV5) amplifying virus-like particles expressing respiratory syncytial virus (RSV) antigens protect mice against RSV infection |
| Q36873249 | Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses |
| Q40065065 | Premature stop codons in the G glycoprotein of human respiratory syncytial viruses resistant to neutralization by monoclonal antibodies. |
| Q33783066 | Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge |
| Q36780345 | Processing, surface expression, and immunogenicity of carboxy-terminally truncated mutants of G protein of human respiratory syncytial virus |
| Q34255436 | Productive infection of isolated human alveolar macrophages by respiratory syncytial virus |
| Q35566601 | Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years |
| Q36920330 | Protection against lethal measles virus infection in mice by immune-stimulating complexes containing the hemagglutinin or fusion protein. |
| Q45859084 | Protection of BALE/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein |
| Q33554501 | Protection of mice from fatal measles encephalitis by vaccination with vaccinia virus recombinants encoding either the hemagglutinin or the fusion protein |
| Q39877929 | Protection of mice from respiratory Sendai virus infections by recombinant vaccinia viruses |
| Q33829701 | Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene |
| Q40797384 | Proteolytic activation of respiratory syncytial virus fusion protein. Cleavage at two furin consensus sequences |
| Q38617302 | Recent advances in the development of subunit-based RSV vaccines. |
| Q45856186 | Recognition of respiratory syncytial (RS) virus proteins by human and BALB/C CD4+ lymphocytes |
| Q35070176 | Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease |
| Q36918751 | Recombinant vaccinia viruses carrying the N gene of human respiratory syncytial virus: studies of gene expression in cell culture and immune response in mice |
| Q39539804 | Recovery and characterization of a chimeric rinderpest virus with the glycoproteins of peste-des-petits-ruminants virus: homologous F and H proteins are required for virus viability |
| Q37611890 | Rescue of synthetic analogs of respiratory syncytial virus genomic RNA and effect of truncations and mutations on the expression of a foreign reporter gene |
| Q36691093 | Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by ant |
| Q30240274 | Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment |
| Q36683018 | Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived |
| Q41838015 | Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses |
| Q36586879 | Respiratory syncytial virus entry inhibitors targeting the F protein |
| Q36930001 | Respiratory syncytial virus group-specific antibody response in nasopharyngeal secretions from infants and children after primary infection |
| Q36797478 | Respiratory syncytial virus infection in C57BL/6 mice: clearance of virus from the lungs with virus-specific cytotoxic T cells |
| Q36875715 | Role of individual glycoproteins of human parainfluenza virus type 3 in the induction of a protective immune response |
| Q33976286 | Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease |
| Q45359023 | Selection and characterization of human respiratory syncytial virus escape mutants resistant to a polyclonal antiserum raised against the F protein |
| Q37308711 | Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections |
| Q37170484 | Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F and G glycoproteins after first, second, and third infections |
| Q45377065 | Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection. |
| Q37217484 | Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections. |
| Q41138576 | Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection |
| Q36827291 | The 1A protein of respiratory syncytial virus is an integral membrane protein present as multiple, structurally distinct species |
| Q34337480 | The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins |
| Q45323698 | The Heptad Repeat C Domain of the Respiratory Syncytial Virus Fusion Protein Plays a Key Role in Membrane Fusion |
| Q38367554 | The Pneumovirinae fusion (F) protein: A common target for vaccines and antivirals |
| Q36641979 | The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice. |
| Q39592019 | The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate |
| Q87098753 | The live vector approach-viruses |
| Q45734682 | The ovine respiratory syncytial virus F gene sequence and its diagnostic application |
| Q42615478 | The respiratory syncytial virus subgroup B attachment glycoprotein: analysis of sequence, expression from a recombinant vector, and evaluation as an immunogen against homologous and heterologous subgroup virus challenge |
| Q36994686 | The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes |
| Q40746072 | Treatment and prevention options for respiratory syncytial virus infections |
| Q40686662 | Use of a vesicular stomatitis virus complementation system to analyze respiratory syncytial virus binding |
| Q39706637 | Use of vaccinia virus to express biopharmaceutical products |
| Q33558356 | Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice |
| Q38776417 | Vaccinia virus expression vectors |
| Q34211635 | Vaccinia virus vectors: new strategies for producing recombinant vaccines |
| Q36315159 | Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats |
| Q91908704 | Viral pneumonia in children |
Search more.